James N Ingle

James N Ingle

UNVERIFIED PROFILE

Are you James N Ingle?   Register this Author

Register author
James N Ingle

James N Ingle

Publications by authors named "James N Ingle"

Are you James N Ingle?   Register this Author

100Publications

3517Reads

48Profile Views

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.

Breast Cancer Res Treat 2019 Aug 22;176(3):709-716. Epub 2019 May 22.

Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05264-2DOI Listing
August 2019

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.

J Clin Oncol 2019 Aug 18;37(22):1982-1983. Epub 2019 Jun 18.

Matthew P. Goetz, MD and Vera J. Suman, PhD, Mayo Clinic, Rochester, MN; Yusuke Nakamura, MD, PhD and Kazuma Kiyotani, PhD, Cancer Precision Medicine Center, Tokyo, Japan; V. Craig Jordan, PhD, DSc, The University of Texas MD Anderson Cancer Center, Houston, TX; and James N. Ingle, MD, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/JCO.19.00504
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675592PMC
August 2019

4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.

Breast Cancer Res Treat 2019 Jun 1;175(3):567-578. Epub 2019 Apr 1.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05194-zDOI Listing
June 2019

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.

Breast Cancer Res 2019 04 3;21(1):47. Epub 2019 Apr 3.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1130-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448248PMC
April 2019

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

J Clin Oncol 2018 08 23;36(22):2281-2287. Epub 2018 May 23.

Peter A. Fasching and Matthias Rübner, Erlangen University Hospital, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen; Sibylle Loibl, Valentina Nekljudova, Karsten E. Weber, and Gunter von Minckwitz, German Breast Group Forschungs, Neu-Isenburg; Christian Schem, University Medical Center Schleswig-Holstein, Kiel; Hans Tesch, Centrum für Hämatologie und Onkologie Bethanien, Frankfurt; Michael Untch, Helios-Klinikum, Berlin-Buch; Jörn Hilfrich, Eilenriede-Klinik, Hannover; Mahdi Rezai, Luisenkrankenhaus; Tanja Fehm, Düsseldorf University Hospital, Heinrich-Heine University of Düsseldorf, Düsseldorf; Bernd Gerber, University of Rostock, Rostock; Serban Dan Costa, Magdeburg University Hospital, Magdeburg; Jens-Uwe Blohmer and Cornelia Liedtke, Charité University Hospital Campus Charité-Mitte, Berlin; Jens Huober, University of Ulm; Brigitte Rack, University Hospital Ulm, Ulm; Volkmar Müller, Hamburg University Hospital, Hamburg, Germany; Chunling Hu, Steven N. Hart, Hermela Shimelis, Raymond Moore, James N. Ingle, and Fergus J. Couch, Mayo Clinic; and Richard M. Weinshilboum and Liewei Wang, Mayo Clinic College of Medicine, Mayo Foundation, Rochester, MN.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.2285
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.2285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067803PMC
August 2018

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

N Engl J Med 2018 Jul 4;379(2):122-137. Epub 2018 Jun 4.

From the Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Newcastle, NSW (P.A.F.), and the University of Sydney, Sydney (A.S.C.) - all in Australia; the Institute of Oncology of Southern Switzerland, Ospedale San Giovanni, Bellinzona (O.P.), Breast Cancer St. Gallen, St. Gallen (T.R.), and the International Breast Cancer Study Group Coordinating Center (R.M., M.R.-P., B.R., A.S.C.), University Hospital Inselspital (M.R.-P.), Bern - all in Switzerland; the University of Chicago Medical Center, Chicago (G.F.F.); the University of Calgary, Calgary, AB, Canada (B.A.W.); the Division of Medical Senology, European Institute of Oncology (M.C.), and the European Institute of Oncology and International Breast Cancer Study Group (A.G.), Milan, Ospedale Papa Giovanni XXIII, Bergamo (C.T.), Azienda Socio Sanitaria Territoriale Sette Laghi-Ospedale di Circolo and Fondazione Macchi, Varese (G.P.), Medical Oncology and Cancer Prevention, IRCCS, National Cancer Institute, Aviano (F.P., S.S.), the Department of Medicine, School of Medical Oncology, University of Udine, Udine (F.P.), Salvatore Maugeri Foundation, Pavia (L.P.), and the Hospital of Prato-Azienda Unità Sanitaria Locale Toscana Centro, Prato (A.D.L.) - all in Italy; the National Institute of Oncology, Budapest, Hungary (I.L.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.); University Hospital 12 de Octubre, Madrid (E.C.), Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (M.B.), and Instituto Valenciano de Oncologia, Valencia (M.A.C.) - all in Spain; the Susan F. Smith Center for Women's Cancers (H.J.B., E.P.W.) and the International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology (R.D.G., M.M.R.), Dana-Farber Cancer Institute, Harvard Medical School, the Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation (R.D.G.) - all in Boston; Institut Bergonié Comprehensive Cancer Center, Université de Bordeaux, Bordeaux, France (H.R.B., M.D.); the Angeles Clinic and Research Institute, Santa Monica, CA (S.M.); Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond (C.E.G.); Mayo Clinic, Rochester, MN (M.P.G., J.N.I.); Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (V.S.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (N.E.D.); Weston Park Hospital, Sheffield, United Kingdom (R.C.); and the Department of Obstetrics and Gynecology, University Medical Center, Regensburg, Germany (S.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1803164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193457PMC
July 2018

, a Novel Transcription Factor and a Coregulator of Nuclear Factor B p65: Single Nucleotide Polymorphism and Estrogen Dependence.

J Pharmacol Exp Ther 2018 06 28;365(3):700-710. Epub 2018 Mar 28.

Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (M.H., E.L.d.R., C.Z., L.W., H.L., R.M.W.), and Division of Medical Oncology, Department of Oncology (J.N.I.), Mayo Clinic, Rochester, Minnesota; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts (P.E.G.); Canadian Cancer Trials Group, Kingston, Ontario, Canada (L.E.S.); and RIKEN Center for Integrative Medical Science, Yokohama, Japan (M.K.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.118.247718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954488PMC
June 2018

Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.

Biochem Pharmacol 2018 06 3;152:279-292. Epub 2018 Apr 3.

Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2018.03.032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960634PMC
June 2018

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.

Breast Cancer Res Treat 2018 Apr 30;168(3):639-647. Epub 2017 Dec 30.

Division of Medical Oncology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4616-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842248PMC
April 2018

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

J Clin Oncol 2018 02 12;36(6):563-571. Epub 2018 Jan 12.

Julie Lemieux, Centre Hospitalier Universitaire de Québec, Quebec City, Quebec; Michael D. Brundage, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Wendy R. Parulekar, Kate Whelan, and Dongsheng Tu, Canadian Cancer Trials Group, Kingston; Kathleen I. Pritchard, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto; Timothy J. Whelan, McMaster University and Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada; Paul E. Goss, Massachusetts General Hospital Cancer Center, Boston, MA; James N. Ingle, North Central Cancer Treatment Group, Mayo Clinic, Rochester, NY; Paul Celano; Greater Baltimore Medical Center, Baltimore, MD; Hyman Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Julie Gralow, University of Washington, Seattle, WA; and Kathrin Strasser-Weippl, Wilhelminen Hospital, Vienna, Austria.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.7500
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.7500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815404PMC
February 2018

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer.

Oncotarget 2017 Nov 11;8(57):96506-96521. Epub 2017 Oct 11.

Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/21787
Publisher Site
http://dx.doi.org/10.18632/oncotarget.21787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722501PMC
November 2017

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

J Clin Oncol 2017 Oct 30;35(30):3391-3400. Epub 2017 Aug 30.

Matthew P. Goetz, Vera J. Suman, Joel M. Reid, Don W. Northfelt, Michael A. Mahr, Andrew T. Ralya, Mary Kuffel, Sarah A. Buhrow, Stephanie L. Safgren, Renee M. McGovern, John Black, Travis Dockter, Tufia Haddad, Charles Erlichman, Alex A. Adjei, Dan Visscher, Benjamin R. Kipp, Minetta C. Liu, John R. Hawse, Matthew M. Ames, and James N. Ingle, Mayo Clinic, Rochester, MN; Zachary R. Chalmers and Garrett Frampton, Foundation Medicine, Cambridge, MA; and John R. Hawse, James H. Doroshow, Jerry M. Collins, and Howard Streicher, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.3246
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.3246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648176PMC
October 2017

SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1.

PLoS Genet 2017 Oct 2;13(10):e1007031. Epub 2017 Oct 2.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pgen.1007031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638617PMC
October 2017

Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-B Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.

Mol Pharmacol 2017 08 14;92(2):175-184. Epub 2017 Jun 14.

Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (M.-F.H., L.W., R.M.W.), Division of Medical Oncology, Department of Oncology (J.N.I.), and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota; Department of Emergency Medicine, Vanderbilt Medical Center, Nashville, Tennessee (T.B.); Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts (P.E.G.); NCIC Clinical Trials Group, Kingston, Ontario Canada (L.E.S.); and RIKEN Center for Integrative Medical Science, Tsurumi-ku, Yokohama, Japan (T.M., M.K.)

View Article

Download full-text PDF

Source
http://molpharm.aspetjournals.org/lookup/doi/10.1124/mol.117
Publisher Site
http://dx.doi.org/10.1124/mol.117.108340DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508195PMC
August 2017

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

J Clin Oncol 2017 Mar 21;35(7):751-758. Epub 2016 Nov 21.

Kala Visvanathan, Johns Hopkins University School of Medicine and Bloomberg School of Public Health; MaryJo S. Fackler, Zhe Zhang, Zoila A. Lopez-Bujanda, Stacie C. Jeter, Lori J. Sokoll, Leslie M. Cope, Christopher B. Umbricht, David M. Euhus, Saraswati Sukumar, and Antonio C. Wolff, Johns Hopkins University School of Medicine, Baltimore, MD; Elizabeth Garrett-Mayer, Medical University of South Carolina, Charleston, SC; Andres Forero, University of Alabama at Birmingham, Birmingham, AL; Anna M. Storniolo, Indiana University, Bloomington, IN; Rita Nanda, University of Chicago, Chicago, IL; Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; and James N. Ingle, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455421PMC
March 2017

Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.

J Clin Oncol 2016 11;34(32):3944-3945

Matthew P. Goetz, Mayo Clinic, Rochester, MN; Mark Ratain, The University of Chicago, Chicago, IL; and James N. Ingle, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.5214DOI Listing
November 2016

Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.

N Engl J Med 2016 10;375(16):1591

Queen’s University, Kingston, ON, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1610719DOI Listing
October 2016

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

J Clin Oncol 2016 09 23;34(25):3069-103. Epub 2016 May 23.

Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center; Barbara Fowble, University of California San Francisco, San Francisco; Rita S. Mehta, University of California Irvine, Orange, CA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Erin Macrae, Columbus Oncology and Hematology Associates, Columbus, OH; Debra L. Barton, University of Michigan School of Nursing, Ann Arbor, MI; Hannah Klein Connolly, Patient Representative, Edina, MN; Maura N. Dickler, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Lesley Fallowfield, Sussex Health Outcomes Research and Education in Cancer, Brighton and Sussex Medical School, University of Sussex, Sussex; Stephen R.D. Johnston, Royal Marsden Hospital, London, United Kingdom; James N. Ingle, Mayo Clinic, Rochester, MN; Mohammad Jahanzeb, University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach, FL; Larissa A. Korde, University of Washington, Seattle, WA; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1487DOI Listing
September 2016

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

N Engl J Med 2016 Jul 5;375(3):209-19. Epub 2016 Jun 5.

From the Massachusetts General Hospital Cancer Center, Avon International Breast Cancer Research Program (P.E.G.), Harvard Medical School (P.E.G., E.W.), and Dana-Farber Cancer Institute (E.W.), Boston; the Department of Oncology, Mayo Clinic, Rochester, MN (J.N.I., J.S.K.); Sunnybrook Odette Cancer Centre, Toronto (K.I.P.), British Columbia Cancer Agency, Vancouver (K.G.), Canadian Cancer Trials Group, Queen's University, Kingston, ON (K.W., D.T., W.R.P.), Department of Oncology, McMaster University, Hamilton, ON (T.W.), and Dalhousie University Faculty of Medicine, Moncton Hospital, Moncton, NB (S.R.) - all in Canada; Virginia Cancer Specialists-US Oncology Network, Fairfax (N.J.R.); University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill (H.M.); University of Washington School of Medicine, Seattle (J.G.); Center of Oncology and Hematology, Wilheminen Hospital, Vienna (K.S.-W.); Colorado Cancer Research Program, Denver (K.S.); Johns Hopkins Kimmel Cancer Center, Baltimore (A.C.W.); Memorial Sloan Kettering Cancer Center, New York (C.H.); University of Arizona, Tucson (A.S.); and Highlands Oncology Group, Fayetteville, AR (J.T.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1604700DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024713PMC
July 2016

Reply to C. Shah et al.

J Clin Oncol 2016 05 21;34(15):1824-5. Epub 2016 Mar 21.

University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4714DOI Listing
May 2016

Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.

Mol Endocrinol 2016 Mar 11;30(3):382-98. Epub 2016 Feb 11.

Division of Clinical Pharmacology (M.-F.H., M.L., L.W., R.M.W.), Department of Molecular Pharmacology and Experimental Therapeutics, Division of Rheumatology (M.-F.H., T.B.), Department of Medicine, Division of Biomedical Statistics and Informatics (K.R.K.), Department of Health Sciences Research, and Division of Medical Oncology (M.P.G., J.N.I.), Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905; Division of Hematology/Oncology (P.E.G.), Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard University, Boston, Massachusetts 02114; National Cancer Institute of Canada Clinical Trials Group (L.E.S.), Kingston, Ontario, Canada K7L 3N6; and RIKEN Center for Integrative Medical Science (M.K.), Yokohama 230-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/me.2015-1267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771694PMC
March 2016

Evaluation of the Aromatase Inhibition Potential of Freeze-Dried Grape Powder.

J Diet Suppl 2015 Dec 28;12(4):373-382. Epub 2014 Aug 28.

c 3 Health Sciences Research Department , Mayo Clinic College of Medicine Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/19390211.2014.952863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873455PMC
December 2015

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

J Clin Oncol 2015 Nov 14;33(33):3938-44. Epub 2015 Sep 14.

Lawrence J. Solin, Albert Einstein Healthcare Network, Philadelphia; Nancy E. Davidson, University of Pittsburgh, Pittsburgh, PA; Robert Gray, Dana-Farber Cancer Institute; Abram Recht, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston; Mary Ann Lowen, Baystate Medical Center, Springfield, MA; Lorie L. Hughes, Harris Radiation Therapy Center at Gordon Hospital, Calhoun; William C. Wood, Emory University, Atlanta, GA; Sunil S. Badve, Indiana University, Indianapolis, IN; Frederick L. Baehner, University of California, San Francisco, San Francisco, CA; James N. Ingle, Mayo Clinic, Rochester, MN; Edith A. Perez, Mayo Clinic, Jacksonville, FL; and Joseph A. Sparano, Montefiore Medical Center, Bronx, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8588DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652014PMC
November 2015

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).

J Natl Cancer Inst 2015 Sep 25;107(9). Epub 2015 Jun 25.

Dana-Farber Cancer Institute, Boston, MA (JAL, EW); Alliance Statistics and Data Center, Durham, NC (CTC); Mayo Clinic, Rochester, MN (ML, JNI); Hofstra North Shore - LIJ School of Medicine, ProHEALTH Care Associates, Lake Success, NY (MC); Northwestern University Feinberg School of Medicine, Chicago, IL (WG); The Angeles Clinic and Research Institute, Santa Monica, CA (SM); Rhode Island Hospital, Providence, RI (WS); St. Barnabas Medical Center, Livingston, NJ (RM); The Genome Institute, Washington University in St. Louis, St. Louis, MO (EM); Department of Genetics, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC (CMP); Breast Cancer Program, Siteman Cancer Center and Washington University School of Medicine, St. Louis, MO (ME); Memorial Sloan Kettering Cancer Center, New York, NY (CAH); Alliance Statistics and Data Center, MD Anderson Cancer Center, Houston, TX (DB); Alliance Statistics and Data Center, Dana-Farber Cancer Institute, Boston, MA (WTB).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/9/djv179.full.pdf
Web Search
http://dx.doi.org/10.1093/jnci/djv179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651106PMC
September 2015

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.

Pharmacogenet Genomics 2015 Apr;25(4):157-63

Departments of aOncology bMolecular Pharmacology and Experimental Therapeutics cBiostatistics dLaboratory Medicine, Mayo Clinic, Rochester, Minnesota eDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona fCambridge Isotope Laboratories Inc. gPhysical Sciences Inc., Andover, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356640PMC
April 2015

Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells.

PLoS One 2014 9;9(5):e96995. Epub 2014 May 9.

Department of Medical Oncology, Mayo Clinic College Of Medicine, Rochester, Minnesota, United States of America; Department of Biochemistry and Molecular Biology, Mayo Clinic College Of Medicine, Rochester, Minnesota, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0096995PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016211PMC
January 2015

Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.

J Clin Oncol 2015 Jan 15;33(3):265-71. Epub 2014 Dec 15.

Vered Stearns, Kimmel Cancer Center, Johns Hopkins, Baltimore, MD; Judith-Anne W. Chapman, Aurélie Le Maitre, Jessica Kundapur, and Lois E. Shepherd, NCIC Clinical Trials Group, Queen's University, Kingston; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Cynthia X. Ma, Siteman Cancer Center, Washington University, St Louis, MO; Matthew J. Ellis, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; James N. Ingle, Mayo Clinic, Rochester, MN; G. Thomas Budd, Cleveland Clinic, Cleveland, OH; George W. Sledge, Stanford University, San Francisco, CA; Pedro E.R. Liedke and Paul E. Goss, Harvard University; Paul E. Goss, Avon International Breast Cancer Research Program, Massachusetts General Hospital, Boston, MA; Manuela Rabaglio, Inselspital University Hospital and International Breast Cancer Study Group Coordinating Center, Berne, Switzerland; and Pedro E.R. Liedke, Hospital de Clínicas de Porto Alegre and Instituto do Cancer Mãe de Deus, Oncologia, Porto Alegre, Rio Grande do Sul, Brazil.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/3/265.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.6926
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.6926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289722PMC
January 2015

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

J Clin Oncol 2014 Dec 27;32(35):3948-58. Epub 2014 Oct 27.

Amye J. Tevaarwerk, University of Wisconsin, Madison, WI; Molin Wang, Harvard University; Fengmin Zhao, Dana-Farber Cancer Institute, Boston, MA; John H. Fetting, Johns Hopkins University, Baltimore, MD; David Cella and Lynne I. Wagner, Northwestern University, Chicago, IL; Silvana Martino, Angeles Clinic and Research Institute, Santa Monica, CA; James N. Ingle, Mayo Clinic, Rochester, MN; Joseph A. Sparano, Montefiore Medical Center, Bronx, NY; Lawrence J. Solin, Albert Einstein Medical Center, Philadelphia, PA; William C. Wood, Emory University, Atlanta, GA; and Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.6993DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251958PMC
December 2014

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

J Natl Cancer Inst 2014 Dec 8;107(2). Epub 2014 Dec 8.

Department of Oncology (MPG, MMA, JNI), Department of Health Sciences Research (VJS, KRK), and Department of Molecular Pharmacology and Experimental Therapeutics (MPG, SLS, MK, MMA), Mayo Clinic, Rochester, MN; Department of Genetics, University of North Carolina, Chapel Hill, NC (GOS, CMP); Center for Personalized Therapeutics, University of Chicago, Chicago, IL (YN, NJC, MJR); Foundation Medicine Inc., Cambridge, MA (JXS, PJS, VAM, JSR, RY); Novartis Pharmaceuticals Corporation, East Hanover, NJ (DC); Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY (JSR); Division of Hematology/Oncology, Vanderbilt University, Nashville, TN (HG); Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (AMGA, OB); Department Breast Cancer Susceptibility and Pharmacogenomics, Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, University Tuebingen, German Cancer Consortium (DKTK) and German Cancer Research (DKTK), Heidelberg, Germany (HB).Current affiliation of H. Gomez: Departamento de Medicina Oncologica, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565524PMC
December 2014

Reply to P. Niravath et Al.

J Clin Oncol 2014 Nov 25;32(33):3780-1. Epub 2014 Aug 25.

Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.9235DOI Listing
November 2014

Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.

Mol Endocrinol 2014 Oct 22;28(10):1740-51. Epub 2014 Aug 22.

Division of Clinical Pharmacology (M.L., L.W., R.M.W.), Department of Molecular Pharmacology and Experimental Therapeutics; Departments of Oncology (J.N.I.) and Health Sciences Research (A.B., G.D.J., E.E.C., D.J.S.); and Division of Endocrinology (S.K.), Mayo Clinic, Rochester, Minnesota 55905; Massachusetts General Hospital (P.E.G.), Harvard University, Boston, Massachusetts 02114; Rikagaku Kenkyūsho Center for Integrative Medical Science (M.K., Y.F.), Yokohama, Japan 230-0045; School of Medicine (Y.N.), Chicago University, Chicago, Illinois 60637; National Cancer Institute of Canada Clinical Trials Group (J.-A.W.C., L.E.S.), Kingston, Ontario, Canada K7L 3N6; and Division of Oncology (M.J.E.), Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/me.2014-1147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179631PMC
October 2014

Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.

Authors:
Kristen S Purrington Susan Slager Diana Eccles Drakoulis Yannoukakos Peter A Fasching Penelope Miron Jane Carpenter Jenny Chang-Claude Nicholas G Martin Grant W Montgomery Vessela Kristensen Hoda Anton-Culver Paul Goodfellow William J Tapper Sajjad Rafiq Susan M Gerty Lorraine Durcan Irene Konstantopoulou Florentia Fostira Athanassios Vratimos Paraskevi Apostolou Irene Konstanta Vassiliki Kotoula Sotiris Lakis Meletios A Dimopoulos Dimosthenis Skarlos Dimitrios Pectasides George Fountzilas Matthias W Beckmann Alexander Hein Matthias Ruebner Arif B Ekici Arndt Hartmann Ruediger Schulz-Wendtland Stefan P Renner Wolfgang Janni Brigitte Rack Christoph Scholz Julia Neugebauer Ulrich Andergassen Michael P Lux Lothar Haeberle Christine Clarke Nirmala Pathmanathan Anja Rudolph Dieter Flesch-Janys Stefan Nickels Janet E Olson James N Ingle Curtis Olswold Seth Slettedahl Jeanette E Eckel-Passow S Keith Anderson Daniel W Visscher Victoria L Cafourek Hugues Sicotte Naresh Prodduturi Elisabete Weiderpass Leslie Bernstein Argyrios Ziogas Jennifer Ivanovich Graham G Giles Laura Baglietto Melissa Southey Veli-Matti Kosma Hans-Peter Fischer Malcom W R Reed Simon S Cross Sandra Deming-Halverson Martha Shrubsole Qiuyin Cai Xiao-Ou Shu Mary Daly Joellen Weaver Eric Ross Jennifer Klemp Priyanka Sharma Diana Torres Thomas Rüdiger Heidrun Wölfing Hans-Ulrich Ulmer Asta Försti Thaer Khoury Shicha Kumar Robert Pilarski Charles L Shapiro Dario Greco Päivi Heikkilä Kristiina Aittomäki Carl Blomqvist Astrid Irwanto Jianjun Liu Vernon Shane Pankratz Xianshu Wang Gianluca Severi Arto Mannermaa Douglas Easton Per Hall Hiltrud Brauch Angela Cox Wei Zheng Andrew K Godwin Ute Hamann Christine Ambrosone Amanda Ewart Toland Heli Nevanlinna Celine M Vachon Fergus J Couch

Carcinogenesis 2014 May 9;35(5):1012-9. Epub 2013 Dec 9.

Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgt404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004200PMC
May 2014

Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.

J Clin Oncol 2014 May 7;32(14):1427-36. Epub 2014 Apr 7.

Elizabeth Maunsell, Centre de recherche du Centre hospitalier universitaire (CHU) de Québec, (Axe Oncologie), Québec; Pierre Dubé, Hôpital Maisonneuve-Rosemont, Montreal, QC; Andrew L. Cooke, CancerCare Manitoba, Winnipeg, MB; Silvana Spadafora, Algoma District Cancer Program, Sault Ste. Marie, ON; Lavina Lickley, Women's College Hospital; Angela M. Cheung, University Health Network, University of Toronto, Toronto; Dianne Johnston, Andrea Hiltz, Michael Brundage, Dongsheng Tu, and Harriet Richardson, National Cancer Institute of Canada Clinical Trials Group; Joseph Pater, Queens University, Kingston, ON; Susan L. Ellard, British Columbia Cancer Agency-Southern Interior, Kelowna; Karen A. Gelmon, British Columbia Cancer Agency, Vancouver, BC, Canada; Paul E. Goss, Massachusetts General Hospital, Boston, MA; Rowan T. Chlebowski, University of California at Los Angeles Medical Centre, Torrance, CA; James N. Ingle and Sandhya Pruthi, Mayo Clinic, Rochester, MN; José E. Alés Martínez, Hospital N. S. Sonsoles, Ávila; Amparao Ruiz, Instituto Valenciano de Oncologia, Valencia, Spain; Gloria E. Sarto, Center for Women's Health & Health Research, University of Wisconsin, Madison, WI; Carol J. Fabian, University of Kansas Medical Center, Kansas City, KS; Pascal Pujol, CHU-Hôpital Arnaud de Villeneuve, Montpellier, France; Susan Hendrix, Hutzel Women's Health Specialists, Detroit, MI; Debra W. Thayer, MedStar Health Research Institute, Hyattsville, MD; Kendrith M. Rowland, Carle Cancer Centre/Mills Breast Cancer Institute, Urbana, IL; and Jean Wactawski-Wende, State University of New York at Buffalo, Buffalo, NY.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/04/03/JCO.2013.51
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.51.2483
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.51.2483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879707PMC
May 2014

Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

J Natl Cancer Inst 2014 Apr 3;106(5). Epub 2014 Apr 3.

Affiliations of authors: Department of Oncology (MPG, JNI) and Department of Molecular Pharmacology and Experimental Therapeutics (MPG, RW), Mayo Clinic, Rochester, MN; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (HB); The University of Chicago, Chicago, IL (MJR, NJC, YN).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580553PMC
April 2014

Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.

Cancer Res 2014 Apr;74(8):2160-70

Authors' Affiliations: Departments of Oncology, Surgery, and Surgical Pathology, Johns Hopkins University School of Medicine; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore Maryland; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; Departments of Oncology and Surgery, Mayo Clinic, Rochester, Minnesota; Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327879PMC
April 2014

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Clin Cancer Res 2013 Oct 21;19(19):5505-12. Epub 2013 Aug 21.

Authors' Affiliations: Breast Cancer Medicine Service, Departments of Pathology, Biostatistics, and Radiology, Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University, New York; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, Massachusetts; Mayo Clinic, Rochester, Minnesota; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia; University of North Carolina at Chapel Hill, Chapel Hill; Duke University Medical Center, Durham, North Carolina; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California; University of Alabama at Birmingham, Birmingham, Alabama; and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643PMC
October 2013

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Clin Cancer Res 2013 Oct 21;19(20):5798-807. Epub 2013 Aug 21.

Authors' Affiliations: Section of Biostatistics; Division of Anatomic Pathology, Mayo Clinic, Scottsdale, Arizona; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology; Division of Biomedical Statistics and Informatics and Medical Oncology, Mayo Clinic, Rochester, Minnesota; Division of Anatomic Pathology and Hematology/Oncology, Mayo Clinic, Jacksonville, Florida; Division of Hematology/Oncology, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, Pennsylvania; The Angeles Clinic and Research Institute, Santa Monica, California; Indiana University Medical Center Cancer Pavilion, Indianapolis, Indiana; Division of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa; Seattle Cancer Care Alliance, Seattle, Washington; and Case Western Reserve University, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805021PMC
October 2013

Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.

Authors:
James N Ingle

Breast 2013 Aug;22 Suppl 2:S180-3

Division of Medical Oncology, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.07.035DOI Listing
August 2013

Pharmacogenomics of endocrine therapy in breast cancer.

Authors:
James N Ingle

J Hum Genet 2013 Jun 2;58(6):306-12. Epub 2013 May 2.

Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jhg.2013.35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926210PMC
June 2013

Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies.

Genet Epidemiol 2013 Apr 24;37(3):229-38. Epub 2013 Jan 24.

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gepi.21708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740575PMC
April 2013

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

J Clin Oncol 2013 Jan 22;31(2):176-80. Epub 2012 Oct 22.

Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.44.6625
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.44.6625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731938PMC
January 2013

Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.

Breast Cancer Res Treat 2012 Dec 23;136(3):769-76. Epub 2012 Oct 23.

Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2294-z
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2294-zDOI Listing
December 2012

Evaluation of serum estrogen-DNA adducts as potential biomarkers for breast cancer risk.

J Steroid Biochem Mol Biol 2012 Oct 24;132(1-2):73-9. Epub 2012 Feb 24.

Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsbmb.2012.02.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378787PMC
October 2012

Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.

Breast Cancer Res 2012 Mar 9;14(2):R41. Epub 2012 Mar 9.

Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr3137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446375PMC
March 2012

Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody.

J Cell Biochem 2012 Feb;113(2):711-23

Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.23443DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725124PMC
February 2012

Tissue composition of mammographically dense and non-dense breast tissue.

Breast Cancer Res Treat 2012 Jan 30;131(1):267-75. Epub 2011 Aug 30.

Department of Medicine, Mayo Clinic College of Medicine, Charlton 6-239, 200 First Street SW, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1727-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707294PMC
January 2012

Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.

Genet Epidemiol 2012 Jan 7;36(1):3-16. Epub 2011 Dec 7.

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/gepi.20632
Publisher Site
http://dx.doi.org/10.1002/gepi.20632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310255PMC
January 2012

CYP2D6 and tamoxifen: awaiting the denouement.

J Clin Oncol 2011 Dec 31;29(34):4589-90; author reply 4590-1. Epub 2011 Oct 31.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.38.8611DOI Listing
December 2011